Table 1 Comparison of reported proportions of men detected with incurable metastatic/stage VI prostate cancer through different detection strategies. These studies were done in different populations as indicted and based on different investigation indications
Type of cohort studied | Percent of cancers found presenting with Stage IV/Metastasis at diagnosis | Cited publication |
|---|---|---|
Symptomatic men seen in primary care and referred | 19% | Koo et al. 2020 [12] |
Population based reporting National Prostate Cancer Audit 2019 England and Wales | 13% | NPCA report 2019 (https://www.npca.org.uk/content/uploads/2021/01/NPCA-Annual-Report-2020_-Infographic-140121.pdf/) |
Screening study, men PSA ≥ 3 ng/ml (Gothenburg screening trial) | 2.4% | Hugosson et al. [13] |
Screening study, men PSA ≥ 3 ng/ml (ERSPC screening trial) | 2.5% | Schröder et al. [14] |